Skip to main content

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

Completed · Phase 2 · NCT02782663

Conditions: Crohn's Disease (CD)

At a glance

Research payments reported, 2025
$42,822
U.S. investigators named
11
Sites paid
11
Planned or actual enrollment
107

About the trial

Sponsor
AbbVie
Tested
ABT-494 (drug)
Dates
Started 2016-05-18; completion 2025-07-18
Results posted
Yes

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).

From ClinicalTrials.gov, last updated 2026-08-13. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $42,822 in research payments for this study in 2025 (44 payments).

Products named: Rinvoq

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Benaroya Research Institute at Virginia Mason $8,450
  • Mayo Clinic $6,960
  • Washington Univ Sch of Med $6,916
  • Gastrointestinal Specialists $5,966
  • Gi Reviewers LLC $4,745
  • University of North Carolina $4,625
  • New York University $2,428
  • Gastroenterology Associates Of $1,110
  • Regents of the Univ of California $937
  • University of Florida $491
  • University of Louisville Research Foundation $193

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.